Response to "Etiology and Management of Bleeding during ECMO in a COVID-19 Patient"

We thank Yamada, Ogawa, and Asakura for their interest in our case report describing the management of bleeding in a COVID-19 patient during extracorporeal membrane oxygenation (ECMO). Our report focused on the development of acquired von Willebrand syndrome (AVWS) due to ECMO in a COVID-19 patient...

Full description

Saved in:
Bibliographic Details
Published inJournal of Atherosclerosis and Thrombosis Vol. 28; no. 4; pp. 404 - 405
Main Authors Masaki Hayakawa, Masanori Matsumoto
Format Journal Article
LanguageJapanese
Published Japan Atherosclerosis Society 2021
Online AccessGet full text

Cover

More Information
Summary:We thank Yamada, Ogawa, and Asakura for their interest in our case report describing the management of bleeding in a COVID-19 patient during extracorporeal membrane oxygenation (ECMO). Our report focused on the development of acquired von Willebrand syndrome (AVWS) due to ECMO in a COVID-19 patient in a thrombotic state. Fortunately for us, Yamada et al. expanded the discussion to include disseminated intravascular coagulation (DIC), which is another important cause of bleeding during ECMO. Our patient2) was diagnosed with enhanced-fibrinolytic-type DIC during ECMO treatment, based on the International Society on Thrombosis and Haemostasis (ISTH) diagnostic guidelines for DIC.
ISSN:1340-3478
1880-3873